The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas

PURPOSE: mTOR pathway hyperactivation occurs in nearly 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic. Here we examine the efficacy of the newly discovered ATP-competitive mTOR kinase inhibitors CC214-1 and CC214-2 in glioblastoma, identifying molecular de...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gini, Beatrice, Zanca, Ciro, Guo, Deliang, Matsutani, Tomoo, Masui, Kenta, Ikegami, Shiro, Yang, Huijun, Nathanson, David, Villa, Genaro R., Shackelford, David, Zhu, Shaojun, Tanaka, Kazuhiro, Babic, Ivan, Akhavan, David, Lin, Kelly, Assuncao, Alvaro, Gu, Yuchao, Bonetti, Bruno, Mortensen, Deborah S., Xu, Shuichan, Raymon, Heather K., Cavenee, Webster K., Furnari, Frank B, James, David, Kroemer, Guido, Heath, James, Hege, Kristen, Chopra, Rajesh, Cloughesy, Timothy, Mischel, Paul S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815450/
https://ncbi.nlm.nih.gov/pubmed/24030701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0527
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia